What Happened?
San Francisco, -based Parker-Institute-for-Cancer-Immunotherapy Resigned Theresa LaVallee as Vice President of Translational Medicine and Regulatory Affairs
About the Company
For decades, entrenched infrastructure barriers have slowed progress in the fight against cancer and the development of potent immunotherapies. The Parker Institute for Cancer Immunotherapy breaks down these barriers. The result is groundbreaking new research and an intellectual property model that builds collaboration between researchers, nonprofits and industry all working together to get treatments to patients faster.
About the Person
Theresa LaVallee is Vice President of Translational Medicine and Regulatory Affairs at Parker Institute for Cancer Immunotherapy. Previously, Theresa held various senior legal leadership roles in the industry.
Info Source
News
Short Profile